Potential interactions between digoxin and direct oral anticoagulants: application of cohort & novel case-crossover designs

This study aimed to examine potential drug interactions between direct oral anticoagulants (DOACs) (a drug class to prevent blood clots) and digoxin (treatment of abnormal heart rhythms). We compared a range of clinical outcomes in people prescribed DOAC and digoxin with people prescribed DOAC and beta-blockers (a treatment alternative to digoxin). We also used a new study design (case-crossover design) to compare the risk of clinical outcomes between different periods within a person as a validation. In both study designs, we found no increased risk of bleeding when DOACs are used with digoxin, suggesting combined use does not lead to drug-drug interaction. However, we found an increased risk of all-cause death associated with digoxin in DOAC users which requires further investigation.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Epidemiology
Published
2025-02-05
DOI
https://doi.org/10.1016/j.jclinepi.2025.111709
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Potential interactions between digoxin and direct oral anticoagulants: application of cohort & novel case-crossover designs

Charlotte Warren‐Gash, Angel Y. S. Wong, Liam Smeeth, Krishnan Bhaskaran et al.
Journal of Clinical Epidemiology
Atrial Fibrillation Management and Outcomes
article

Potential interactions between digoxin and direct oral anticoagulants: application of cohort & novel case-crossover designs

Charlotte Warren‐Gash, Angel Y. S. Wong, Liam Smeeth, Krishnan Bhaskaran, Ian Douglas, Amitava Banerjee, Clémence Leyrat
article en

Abstract

This study aimed to examine potential drug interactions between direct oral anticoagulants (DOACs) (a drug class to prevent blood clots) and digoxin (treatment of abnormal heart rhythms). We compared a range of clinical outcomes in people prescribed DOAC and digoxin with people prescribed DOAC and beta-blockers (a treatment alternative to digoxin). We also used a new study design (case-crossover design) to compare the risk of clinical outcomes between different periods within a person as a validation. In both study designs, we found no increased risk of bleeding when DOACs are used with digoxin, suggesting combined use does not lead to drug-drug interaction. However, we found an increased risk of all-cause death associated with digoxin in DOAC users which requires further investigation.

Journal of Clinical EpidemiologyVol. 181
London School of Hygiene & Tropical Medicine (GB), Farr Institute (GB), University College London (GB)
UK Research and Innovation, National Institute for Health and Care Research, British Heart Foundation, Diabetes UK, Innovation and Technology Commission, Medical Research Council
Zero hunger
Openalex Percentile: Top 96%
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Potential interactions between digoxin and direct oral anticoagulants: application of cohort & novel case-crossover designs — Charlotte Warren‐Gash, Angel Y. S. Wong, et al. · Journal of Clinical Epidemiology (2025) | TGRS Research Map | TGRS